Learn about the most clinically influential developments in leveraging immune checkpoint inhibitor–based therapy for first-line, second-line, and maintenance treatment of advanced urothelial carcinoma.
Review expert guidance on integrating erdafitinib and enfortumab vedotin into management of progressive urothelial carcinoma, then get up to date on key data for sacituzumab govitecan and other promising investigational therapies.
Download this short summary slideset of key takeaways from a live presentation on integrating targeted agents into the management of progressive urothelial carcinoma.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.